Skip to content
Search

Latest Stories

North West pharmacies champion national effort to boost MMR vaccine accessibility

North West pharmacies champion national effort to boost MMR vaccine accessibility

Parents of children aged 5 to 11 who are overdue for one or both doses of the vaccine can simply walk into these pharmacies without needing an appointment or a referral from a GP

Several community pharmacies in the north-west have embraced the nationwide rollout of the measles, mumps, and rubella (MMR) vaccine for children aged 5 to 11 who have missed their doses.


These pharmacies are leading the country in initiating the vaccination programme, aimed at supporting a national call and recall of under-vaccinated children and increasing MMR vaccine coverage.

According to NHS England, there are currently 28 participating pharmacies in the North West, with 13 located in Lancashire & South Cumbria and 14 in Cheshire & Merseyside. The scheme will soon expand to include a small number of pharmacies in Greater Manchester.

Tricia Spedding, Regional Deputy Head of Public Health for NHS England – North West, emphasised the importance of measles prevention, highlighting its severe complications such as blindness, deafness, and brain swelling.

She cautioned that children who haven't received both doses of the MMR vaccine are vulnerable to this preventable disease.

"By offering the MMR vaccine in pharmacies to children who missed one or both doses, we are hoping to make it easier and more convenient for parents to get their children protected," Spedding commented.

Michael Ball, a pharmacist clinician at Broadway Pharmacy in Preston, Lancashire, participating in the pilot initiative, highlighted that pharmacists can address vaccine hesitancy and provide informed healthcare advice, contributing to increased vaccination rates.

"Offering MMR vaccines at community pharmacies provides patients with the chance to access services within their local community at a convenient time, enhancing accessibility and ultimately increasing vaccination rates," he said.

The current MMR vaccine uptake in the North West stands at 85.2 per cent, below the World Health Organisation's target of 95 per cent coverage, with two doses of MMR vaccine by the age of 5.

To address this, various initiatives have been introduced, including vaccine catch-up clinics in general practice, community outreach clinics, and extra vaccination sessions in schools.

Parents are urged to ensure their children are vaccinated promptly, with GPs actively reaching out to vaccinate children aged 12 months to 5 years.

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less